A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
To reduce the risk of this occurring, patients are given up to eight litres of IV fluid in the first two days after a kidney transplant.
The BEST Fluids trial compared the use of two intravenous (IV) fluids, Plasma-Lyte 148 and saline, finding Plasma-Lyte 148 reduces the need for dialysis by 25 per cent.
Australian Health Journal spoke with the lead-author of the study, RAH Nephrologist and University of Adelaide researcher, Dr Michael Collins.
Dr Collins provided background by stating, “While both types of fluids have been used during kidney transplantation in recent years, until now there had been little robust evidence to demonstrate which one was the most effective and safest to use.”
During the four-year study, these fluids were trialled in 808 patients with kidney failure, who received a kidney transplant from a deceased organ donor at the RAH and 15 other hospitals in Australia and New Zealand.
Saline is the most common type of IV fluid and contains salt (sodium chloride) and water and has been the standard treatment in kidney transplantation. Plasmalyte 148 is a balanced crystalloid fluid containing a mixture of salts, which more closely resembles what is in human blood.
Researchers at the University of Adelaide and University of Sydney, working with the Australasian Kidney Trials Network team and the ANZDATA Registry at the South Australian Health and Medical Research Institute (SAHMRI), found 30 per cent of participants who received Plasma-Lyte 148 needed dialysis after transplant, compared with 40 per cent of participants who received saline.
Commenting on the findings and potential impact to clinical care, Dr Collins said, “Our finding of a substantial reduction in dialysis with balanced crystalloid compared with saline, without any increase in complications or side effects, provides a strong justification to change clinical practice.”
Using Plasma-Lyte 148 did not result in more complications or side effects compared to saline. At one year after the transplant, both groups had similar levels of kidney function while rates of death, rejection and loss of kidney transplant function were also similar for both groups.
The results of the study are now being used to improve the health of kidney transplant patients in Australia and New Zealand and it is likely that practice will change at transplant units around the world.
Dr Collins added, “Balanced fluids are relatively cheap and widely available, so we hope this practise can now be used for most of the estimated 200,000 kidney transplant operations conducted across the globe each year.”
The BEST Fluids trial was funded by the National Health and Medical Research Council (NHMRC) administered Medical Research Future Fund (MRFF) Australia, the Health Research Council of New Zealand, and the Royal Australasian College of Physicians, with trial fluids supplied by Baxter Australia and New Zealand. The results of the study have been published in The Lancet.
-
Success in WA pilot to observe babies showing delays in social interaction & communication development
Inklings – led by The Kids Research Institute Australia – is a program for babies aged 6-18 months whose communications skills are developing differently to expected milestones. In early 2025 it has completed the first year of a pilot program.
At the time of filming (Nov 2024), Inklings has received more then 300 enquiries across WA and started to deliver services to 160 children, with almost 60 who have completed the program.
-
Inaugural Rural and Remote Health Awards
Rural communities are a foundation of the economy and society and must be kept healthy.
There are significant personal, professional and financial rewards for rural healthcare professionals. However, there are also challenges – isolation, long hours, confusion about where to turn for support.
To acknowledge and celebrate the work of Rural and Remote Health Professionals, Rural Health Pro have launched the inaugural National Rural and Remote Health Awards.
-
Strengthening Evidence Through Health Research Where Most People Access Healthcare
In February 2025, the Australian Government committed over $22 million for primary care research, including $5.2m awarded to Professor Michael Kidd, Director of the International Centre for Future Health Systems at UNSW and recently appointed Australia’s Chief Medical Officer, to lead the establishment of one of the largest research collaborations in Australia focused on improving primary care.
The Royal Australian College of GPs says a new national multidisciplinary consortium for primary care research is a positive step forward to improve patient care.
